Revolution Medicines to Participate in March 2025 Investor Conferences
REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in three upcoming investor conferences.
Details of the company's participation are as follows:
TD Cowen 45th Annual Healthcare Conference
Fireside Chat Date/Time: Monday, March 3 at 1:50 p.m. ET
Barclays 27th Annual Global Healthcare Conference
Fireside Chat Date/Time: Tuesday, March 11 at 8:00 a.m. ET
2025 Leerink Partners Global Healthcare Conference
Fireside Chat Date/Time: Wednesday, March 12 at 2:20 p.m. ET
To listen to a live webcast of any of these events, or access archived webcasts, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcasts, replays will be available on the company's website for at least 14 days.
About Revolution Medicines, Inc.Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company's pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.
Revolution Medicines Media & Investor Contact:media@revmed.cominvestors@revmed.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Fraudulent OB/GYN sentenced to 10 years in prison
CHICAGO — A fraudulent OB/GYN, who pleaded guilty last summer for bilking Medicaid and private insurance, has been sentenced to 10 years in prison. Dr. Mona Ghosh owned Progressive Women's Healthcare, located in Hoffman Estates, and was accused of submitting fraudulent claims to Medicaid and other private insurance companies from 2018 to 2022. A total of 17 women spoke during the federal sentencing hearings, which concluded Monday morning after being adjourned on May 29. Several women told stories of how Ghosh charged their insurance companies for visits that didn't happen. Others described the unnecessary tests and procedures she performed. 'I felt like she supported me. In turn, when I'm finding the medical bills coming back for things that never happened, she fed on my vulnerability, on my weakness,' a woman said. Several women shared that they went to Ghosh for a routine pap smear, or cervical cancer screening, and were told results were abnormal. Fearful that they could have cancer, they agreed to get a biopsy. Witnesses said while they were sedated, Ghosh performed other procedures instead, including ones they said have affected their fertility. 17 women share emotional experiences during sentencing of fraudulent OB/GYN Ghosh directed her own employees to submit the fraudulent claims as well. She admitted in the plea agreement that she is accountable for more than $1.5 million. The judge Monday ordered restitution to insurance providers of $1.5 million. Restitution to the victims was ordered in the amount of $605.02. The judge explained that he could only impose restitution to patients based on actual losses for unnecessary and unwanted procedures under specific situations. She has surrendered her medical license and must serve a minimum of two years before being eligible for supervised release. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
13 minutes ago
- Yahoo
Congress should think again about foreign investor tax: UK ambassador to US
British Ambassador to the U.S. Peter Mandelson is appealing to Congress to think again about the proposed new retaliatory tax on certain foreign investment in the US. 'I think that there's something wrong in principle that you should punish a country's businesses and individuals in America because you don't like what their governments are doing at home,' Mandelson said of Section 899 of the House's 'big, beautiful bill' to implement Trump's agenda. Section 899 would create a retaliatory tax on nationals of countries that impose 'unfair foreign taxes' on American businesses. 'If you've got an argument with their governments, then take it out on the governments. Don't take it out on the businesses and the individuals,' he added. Mandelson also believes that this new foreign investor tax is 'counterproductive' for the United States. 'If you're creating such a risk or potential uncertainty tax on businesses here, then many will think twice about investing further in the United States. I would ask Congress to think again about 899,' he said. According to Mandelson, both Congress and the Trump administration should resolve these matters by negotiation, and 'not by means of a legislative bludgeon', where he says the 'innocent are being punished because it's felt that revenge is due against a country and it's taken out on businesses and individuals here in the US.' He added that Section 899 also sets a 'very difficult precedent,' and it's better resolved by 'government to government negotiation and by discretionary means, not statutory ones.' The provision has stoked concerns on Wall Street over whether foreign investors would pull out of U.S. investments over fears of retribution from Trump. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
19 minutes ago
- Yahoo
Musk-Trump Space Showdown Sends Rocket Lab Shares Soaring
June 9 - Rocket Lab USA Inc (NASDAQ:RKLB) shares climbed about 8% on Monday as investors reacted to a weekend spat between SpaceX CEO Elon Musk and former President Donald Trump. The feud began when Musk criticized Trump's proposed tax legislation on X, prompting Trump to suggest cutting Musk's government contracts. Musk fired back, hinting he might decommission SpaceX's Dragon spacecraft, currently the only U.S. vehicle for ferrying astronauts to the International Space Station, before retracting the comment. Over the weekend, Musk posted that we have got the spaceships, and they do not, implying U.S. reliance on SpaceX. That argument appears to be fueling interest in rival aerospace firms. RKLB, which holds multiple NASA contracts and is viewed as a contender for Trump's $175 billion Golden Dome missile defense initiative, saw its stock hit $31.21 in morning trading. AST SpaceMobile Inc (NASDAQ:ASTS) shares surged about 17% after reports suggested U.S. policymakers may look beyond SpaceX for various space investments. ASTS, a top customer of Blue Origin, inked a November launch deal with Jeff Bezos' company to deploy up to 45 satellites. Both RKLB and ASTS traded on above-average volume, signaling heightened investor focus on alternative space players amid the high-profile Musk-Trump clash. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
